Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice

Brain Research Bulletin

Volumn 75, Issue 5, 2008, Pages 598-609

  Toscano, Christopher D ^a   Ueda, Yumi ^b   Tomita, York A ^b   Vicini, Stefano ^c   Bosetti, Francesca ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

3H kainate autoradiography; Endocannabinoid; Excitotoxicity; Fluoro Jade B; GABA; Racine seizure scale

Indexed keywords

BIOLOGICAL MARKER; CANNABINOID RECEPTOR; CELECOXIB; KAINIC ACID; PROSTAGLANDIN SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BRAIN LEVEL; CONTROLLED STUDY; EXCITOTOXICITY; GABAERGIC SYSTEM; INHIBITORY POSTSYNAPTIC POTENTIAL; MALE; MOUSE; NERVE CELL LESION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RECEPTOR BINDING; SEIZURE;

ANALYSIS OF VARIANCE; ANIMALS; AUTORADIOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; KAINIC ACID; MALE; MEMBRANE POTENTIALS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; NEURONS; PATCH-CLAMP TECHNIQUES; PIPERIDINES; PYRAZOLES; SEIZURES; STATISTICS, NONPARAMETRIC; SULFONAMIDES; SYNAPTIC TRANSMISSION;

EID: 40749099051     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2007.10.004     Document Type: Article

References (74)

1. Akarsu E.S., Mamuk S., and Comert A. Inhibition of pentylenetetrazol-induced seizures in rats by prostaglandin D2. Epilepsy Res. 30 (1998) 63-68
2. Akerman S., Kaube H., and Goadsby P.J. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br. J. Pharmacol. 142 (2004) 1354-1360
3. Alger B.E. Endocannabinoids: getting the message across. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 8512-8513
4. Baik E.J., Kim E.J., Lee S.H., and Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. 843 (1999) 118-129
5. Baran H., Vass K., Lassmann H., and Hornykiewicz O. The cyclooxygenase and lipoxygenase inhibitor BW755C protects rats against kainic acid-induced seizures and neurotoxicity. Brain Res. 646 (1994) 201-206
6. Benkovic S.A., O'Callaghan J.P., and Miller D.B. Sensitive indicators of injury reveal hippocampal damage in C57BL/6J mice treated with kainic acid in the absence of tonic-clonic seizures. Brain Res. 1024 (2004) 59-76
7. +-dependent phospholipase A2. J. Neurochem. 91 (2004) 1389-1397
8. Brickley S.G., Farrant M., Swanson G.T., and Cull-Candy S.G. CNQX increases GABA-mediated synaptic transmission in the cerebellum by an AMPA/kainate receptor-independent mechanism. Neuropharmacology 41 (2001) 730-736
9. Candelario-Jalil E., Ajamieh H.H., Sam S., Martinez G., and Leon Fernandez O.S. Nimesulide limits kainate-induced oxidative damage in the rat hippocampus. Eur. J. Pharmacol. 390 (2000) 295-298
10. Choi S.H., Langenbach R., and Bosetti F. Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappaB pathway and downstream enzymes involved in prostaglandin biosynthesis. J. Neurochem. 98 (2006) 801-811
11. Christensen J.K., Paternain A.V., Selak S., Ahring P.K., and Lerma J. A mosaic of functional kainate receptors in hippocampal interneurons. J. Neurosci. 24 (2004) 8986-8993
12. Ciceri P., Zhang Y., Shaffer A.F., Leahy K.M., Woerner M.B., Smith W.G., Seibert K., and Isakson P.C. Pharmacology of celecoxib in rat brain after kainate administration. J. Pharmacol. Exp. Ther. 302 (2002) 846-852
13. Davies N.M., McLachlan A.J., Day R.O., and Williams K.M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet. 38 (2000) 225-242
14. Dembo G., Park S.B., and Kharasch E.D. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 102 (2005) 409-415
15. Feng Z., Li D., Fung P.C., Pei Z., Ramsden D.B., and Ho S.L. COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 14 (20031927-) 9
16. Fujikawa D.G. Prolonged seizures and cellular injury: understanding the connection. Epilepsy Behav. 7 Suppl. 3 (2005) S3-S11
17. Gatley S.J., Gifford A.N., Volkow N.D., Lan R., and Makriyannis A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. 307 (1996) 331-338
18. Gobbo O.L., and O'Mara S.M. Post-treatment, but not pre-treatment, with the selective cyclooxygenase-2 inhibitor celecoxib markedly enhances functional recovery from kainic acid-induced neurodegeneration. Neuroscience 125 (2004) 317-327
19. Hawkey C.J. COX-2 inhibitors. Lancet 353 (1999) 307-314
20. Hou S.T., and MacManus J.P. Molecular mechanisms of cerebral ischemia-induced neuronal death. Int. Rev. Cytol. 221 (2002) 93-148
21. Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., Morham S., and Ross M.E. Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1294-1299
22. Jablonska B., Smith A.L., Kossut M., and Skangiel-Kramska J. Development of laminar distributions of kainate receptors in the somatosensory cortex of mice. Brain Res. 791 (1998) 325-329
23. Kam P.C., and See A.U. Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 55 (2000) 442-449
24. Katori M., and Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm. Res. 49 (2000) 367-392
25. Kaufmann W.E., Andreasson K.I., Isakson P.C., and Worley P.F. Cyclooxygenases and the central nervous system. Prostaglandins 54 (1997) 601-624
26. Kawaguchi K., Hickey R.W., Rose M.E., Zhu L., Chen J., and Graham S.H. Cyclooxygenase-2 expression is induced in rat brain after kainate-induced seizures and promotes neuronal death in CA3 hippocampus. Brain Res. 1050 (2005) 130-137
27. Kelley K.A., Ho L., Winger D., Freire-Moar J., Borelli C.B., Aisen P.S., and Pasinetti G.M. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am. J. Pathol. 155 (1999) 995-1004
28. Kim J., and Alger B.E. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat. Neurosci. 7 (2004) 697-698
29. Kobayashi M., and Buckmaster P.S. Reduced inhibition of dentate granule cells in a model of temporal lobe epilepsy. J. Neurosci. 23 (2003) 2440-2452
30. Kozak K.R., Crews B.C., Morrow J.D., Wang L.H., Ma Y.H., Weinander R., Jakobsson P.J., and Marnett L.J. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J. Biol. Chem. 277 (2002) 44877-44885
31. Kozak K.R., Prusakiewicz J.J., and Marnett L.J. Oxidative metabolism of endocannabinoids by COX-2. Curr. Pharm. Des. 10 (2004) 659-667
32. Kozak K.R., Rowlinson S.W., and Marnett L.J. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem. 275 (2000) 33744-33749
33. Kunz T., Marklund N., Hillered L., and Oliw E.H. Assessment of the effects of the cyclooxygenase-2 inhibitor rofecoxib on visuospatial learning and hippocampal cell death following kainate-induced seizures in the rat. Brain Res. Cogn. Brain Res. 25 (2005) 826-832
34. Kunz T., and Oliw E.H. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur. J. Neurosci. 13 (2001) 569-575
35. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Lee C.A., Goulding E.H., Kluckman K.D., Kim H.S., and Smithies O. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83 (1995) 483-492
36. Long J.M., Mouton P.R., Jucker M., and Ingram D.K. What counts in brain aging? Design-based stereological analysis of cell number. J. Gerontol. A Biol. Sci. Med. Sci. 54 (1999) B407-B417
37. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der Stelt M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C., and Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88
38. McKhann II G.M., Wenzel H.J., Robbins C.A., Sosunov A.A., and Schwartzkroin P.A. Mouse strain differences in kainic acid sensitivity, seizure behavior, mortality, and hippocampal pathology. Neuroscience 122 (2003) 551-561
39. McLin J.P., and Steward O. Comparison of seizure phenotype and neurodegeneration induced by systemic kainic acid in inbred, outbred, and hybrid mouse strains. Eur. J. Neurosci. 24 (2006) 2191-2202
40. Molinuevo J.L., Llado A., and Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. Am J. Alzheimers Dis. Other. Demen. 20 (2005) 77-85
41. Morham S.G., Langenbach R., Loftin C.D., Tiano H.F., Vouloumanos N., Jennette J.C., Mahler J.F., Kluckman K.D., Ledford A., Lee C.A., and Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83 (1995) 473-482
42. Murase K., Ryu P.D., and Randic M. Excitatory and inhibitory amino acids and peptide-induced responses in acutely isolated rat spinal dorsal horn neurons. Neurosci. Lett. 103 (1989) 56-63
43. Nicolle M.M., Shivers A., Gill T.M., and Gallagher M. Hippocampal N-methyl-d-aspartate and kainate binding in response to entorhinal cortex aspiration or 192 IgG-saporin lesions of the basal forebrain. Neuroscience 77 (1997) 649-659
44. A receptor regulates inhibitory synaptic strength. J. Neurophysiol. 92 (2004) 1718-1727
45. Paxinos G., and Franklin K. The Mouse Brain in Stereotaxic Coordinates. second ed. (2001), Elsevier Science, Oxford, UK
46. Paxinos G., and Watson C. The Rat Brain in Sterotaxic Coordinates. second ed. (1986), Academic Press, Sydney
47. Pepicelli O., Fedele E., Berardi M., Raiteri M., Levi G., Greco A., Ajmone-Cat M.A., and Minghetti L. Cyclo-oxygenase-1 and -2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-d-aspartate receptors in rat hippocampus. J. Neurochem. 93 (2005) 1561-1567
48. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32 (1972) 281-294
49. Rapoport S.I., and Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?. Arch. Gen. Psychiat. 59 (2002) 592-596
50. Rosenkranz R.P. Effects of intracerebroventricular administration of PGE1, E2 and F2alpha on electrically induced convulsions in mice. Prostaglandins 15 (1978) 925-942
51. Rosenkranz R.P., and Killam Jr. K.F. Effects of prostacyclin and 6-keto PGF1alpha on electrically induced convulsions in mice. Life Sci. 23 (1978) 2609-2616
52. Rothstein J.D. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin. Neurosci. 3 (1995) 348-359
53. Sang N., Zhang J., and Chen C. PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J. Physiol. 572 (2006) 735-745
54. Schauwecker P.E. Genetic basis of kainate-induced excitotoxicity in mice: phenotypic modulation of seizure-induced cell death. Epilepsy Res. 55 (2003) 201-210
55. Schauwecker P.E., and Steward O. Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 4103-4108
56. Schmued L.C., and Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874 (2000) 123-130
57. A receptor currents in the hippocampus. J. Neurosci. 25 (2005) 10016-10024
58. Seregi A., Forstermann U., and Hertting G. Decreased levels of brain cyclo-oxygenase products as a possible cause of increased seizure susceptibility in convulsion-prone gerbils. Brain Res. 305 (1984) 393-395
59. Shearman L.P., Rosko K.M., Fleischer R., Wang J., Xu S., Tong X.S., and Rocha B.A. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 14 (2003) 573-582
60. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
61. Steinhauer H.B., and Hertting G. Lowering of the convulsive threshold by non-steroidal anti-inflammatory drugs. Eur. J. Pharmacol. 69 (1981) 199-203
62. Suzuki C.A., and Hierlihy S.L. Renal clearance of domoic acid in the rat. Food Chem. Toxicol. 31 (1993) 701-706
63. Takemiya T., Maehara M., Matsumura K., Yasuda S., Sugiura H., and Yamagata K. Prostaglandin E(2) produced by late induced COX-2 stimulates hippocampal neuron loss after seizure in the CA3 region. Neurosci. Res. 56 (2006) 103-110
64. Toscano C.D., Prabhu V.V., Langenbach R., Becker K.G., and Bosetti F. Differential gene expression patterns in cyclooxygenase-1 and cyclooxygenase-2 deficient mouse brain. Genome Biol. 8 (2007) R14
65. Vicini S., Ferguson C., Prybylowski K., Kralic J., Morrow A.L., and Homanics G.E. GABA(A) receptor alpha1 subunit deletion prevents developmental changes of inhibitory synaptic currents in cerebellar neurons. J. Neurosci. 21 (2001) 3009-3016
66. Wang Q., Yu S., Simonyi A., Sun G.Y., and Sun A.Y. Kainic acid-mediated excitotoxicity as a model for neurodegeneration. Mol. Neurobiol. 31 (2005) 3-16
67. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., and Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11 (1993) 371-386
68. Yao J.K., and Reddy R.D. Metabolic investigation in psychiatric disorders. Mol. Neurobiol. 31 (2005) 193-203
69. Yoshikawa K., Kita Y., Kishimoto K., and Shimizu T. Profiling of eicosanoid production in the rat hippocampus during kainic acid-induced seizure: dual phase regulation and differential involvement of COX-1 and COX-2. J. Biol. Chem. 281 (2006) 14663-14669
70. Yu M., Ives D., and Ramesha C.S. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J. Biol. Chem. 272 (1997) 21181-21186
71. Zeron M.M., Fernandes H.B., Krebs C., Shehadeh J., Wellington C.L., Leavitt B.R., Baimbridge K.G., Hayden M.R., and Raymond L.A. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 25 (2004) 469-479
72. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860
73. Zeytin H.E., Patel A.C., Rogers C.J., Canter D., Hursting S.D., Schlom J., and Greiner J.W. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res. 64 (2004) 3668-3678
74. Zhang M., Moore G.A., Gardiner S.J., and Begg E.J. Determination of celecoxib in human plasma and breast milk by high-performance liquid chromatographic assay. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830 (2006) 245-248